EU Agrees on Measures to Boost Local Production of Essential Medicines

The European Union has reached an agreement on new regulations aimed at increasing the production of critical medicines within Europe. The initiative is designed to address recurring shortages and reduce the region's dependence on pharmaceutical imports from countries outside the EU, particularly in Asia.

In recent years, supply disruptions have led to the unavailability of essential pharmaceuticals in European pharmacies and hospitals. These shortages have affected a range of medicines, including pain relievers, antibiotics, and fever medications for children. To counter these vulnerabilities, EU negotiators have developed a framework that enables public funding to support local manufacturing and strengthen supply chains.

One of the core elements of the agreement is the prioritization of domestically produced medicines in public procurement processes. When awarding contracts for drugs deemed vital and where there is a significant reliance on a limited number of external suppliers, preference will be given to products manufactured within Europe. This measure is designed to foster stable and secure supply chains for essential medications.

The new rules also introduce mechanisms to provide financial incentives proportional to the volume of pharmaceutical ingredients and finished products made within the EU. By doing so, the initiative seeks to encourage investment in European manufacturing facilities and reduce the risk of supply bottlenecks.

To accelerate the availability of critical medicines, the agreement allows for the expedited approval of strategic pharmaceutical projects. Additionally, groups of EU member states will have the option to collaborate on joint procurement of vital drugs, particularly those used to treat rare diseases where market demand may otherwise be insufficient to entice manufacturers.

The definition of 'critical medicines' under the new regulations includes drugs for which there are few or no therapeutic alternatives and for which supply interruptions would pose significant risks to patients' health. The list of such medicines features antibiotics, antithrombotic agents, cancer therapies, and cardiovascular drugs, among others.

According to the European Commission, the proposal to update these pharmaceutical regulations was initially presented in March 2025. The Commission highlights that a variety of factors have contributed to recent supply shortages, including limited production of active ingredients and concentration of manufacturing in a small number of countries. The COVID-19 pandemic underscored these weaknesses, exposing the fragility of global pharmaceutical supply chains.

Statistics from EU health ministries indicate that an estimated 80 to 90 percent of medicines available in Europe are currently produced in Asian countries, primarily China. Despite this, the pharmaceutical sector within the EU employs approximately 800,000 people, emphasizing the significance of the industry to the European economy.

The proposed regulations are pending formal approval by both the European Parliament and the Council of the European Union. This step is largely procedural, given the consensus reached among institutional negotiators. Once enacted, the measures are expected to bolster the EU's capacity to maintain a stable and secure supply of essential medicines for its population.